Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06343064 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Study acronym: KYLIN-1
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study title shortened, about 1 wordv3 See this version in full on ClinicalTrials.gov ↗
  2. Primary completion date: Dec 31, 2024 to Dec 31, 2026 Completion date: Jun 30, 2025 to Dec 31, 2026 · Study title expanded, about 1 wordv2 Show 2 more changesShow less
    • Completion date: Jun 30, 2025 to Dec 31, 2026
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
Trial Details
NCT Number NCT06343064
Lead Sponsor Avistone Biotechnology Co., Ltd.
Conditions Non-Small-Cell Lung Cancer
Enrollment 156 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov